Frontlight ResearchEarly access
WithdrawnPhase 2
Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas
Key facts
- Who runs it
- HonorHealth Research Institute
- Where
- Scottsdale, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 14 Jun 2022
- Ended
- 31 Aug 2025
- Type of study
- Interventional
- Treatments tested
- Pemigatinib 4.5 MG
- Record updated
- 3 July 2023
- Why it stopped
- enrollment challenges
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Age ≥ 18 years of age; male or female
- Capable of providing informed consent and complying with trial procedures
- Histologically or cytologically confirmed adenosquamous carcinoma of the pancreas (ASCP)
- Metastatic or unresectable ASCP patients who have progressed on at least one line of therapy
- FGFR gene fusion, mutation, or rearrangement as determined by standard CLIA-certified FDA-approved genomic panel (e.g. Ashion, Caris, FoundationOne etc.)
- Radiographically measurable or evaluable disease according to RECIST 1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Life expectancy ≥ 12 weeks
- Females of child-bearing potential (defined as a sexually mature woman who (1) has not undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally postmenopausal for at least 24 consecutive months [i.e., has had menses at any time during the preceding 24 consecutive months]) must:; Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis), or agree to use, and be able to comply with, effective contraception without interruption, 28 days prior to starting study treatment (including dose interruptions), and while on study treatment and for 1 week following discontinuation from study treatment ;and,; Have a negative serum pregnancy test (β -hCG) result at screening and agree to ongoing pregnancy testing during the course of the study, and at the end of study participation. This applies even if the subject practices true abstinence* from heterosexual contact
- Male subjects must practice true abstinence* or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 1 week following discontinuation from study treatment, even if he has undergone a successful vasectomy
Who cannot take part
- Patients that have received prior treatment with a selective FGFR inhibitor
- Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug. Topical ketoconazole will be allowed
- Exposure to any therapeutic or investigational agent(s) within 3 weeks prior to initiation of study treatment
- Major surgery within 4 weeks prior to initiation of study treatment
- History of and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcifications
- Current evidence of clinically significant corneal or retinal disorder confirmed by ophthalmologic examination
- Any condition in the opinion of the principal investigator that might interfere with the patient's participation in the study or in the evaluation of the study results
Where in United States
- HonorHealth Research InstituteScottsdale, United States
About the trial
What the trial wants to find out
The purpose of this research is to determine the benefit of pemigatinib in patients with advanced metastatic or surgically unresectable adenosquamous carcinoma of the pancreas who have progressed on previous therapy.
The group in the trial
- PemigatinibTreatment being tested
Participants will be provided with a bottle of pemigatinib tablets on Day 1 of each cycle (one cycle = 21 days). A bottle contains 4.5 mg X 42 tablets total. Each pemigatinib bottle is sufficient for one cycle. Resupply will be provided as necessary on Day 1 of each cycle.
Treatment: Pemigatinib 4.5 MG
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Pemigatinib in Subjects With Advanced Metastatic or Surgically Unresectable Adenosquamous Carcinoma of the Pancreas (ASCP) Who Have Progressed On Previous Therapy
- Record updated
- 3 July 2023